In 2024, Vertex Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Vertex Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Vertex Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
In 2024, the total operational greenhouse gas (GHG) emissions of Vertex Pharmaceuticals amounted to 12,906 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Vertex Pharmaceuticals decreased by 43.19%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a b
In 2024, the total Scope 1 emissions of Vertex Pharmaceuticals were 8,976 metric tons of CO₂ equivalent (tCO₂e). a
Since 2018, Vertex Pharmaceuticals's Scope 1 emissions have increased by 58.47%, reflecting a rising long-term trend in Scope 1 emissions over time. a d
Compared to the previous year (2023), Vertex Pharmaceuticals's Scope 1 emissions increased by 8%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
In 2024, Vertex Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 3,930 tCO₂e using the market-based method. a
Since 2018, Vertex Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 63.9%, reflecting a declining long-term trend in Scope 2 emissions over time. a d
In 2024, Vertex Pharmaceuticals reported its Scope 2 emissions using the market-based method. a
In 2024, Vertex Pharmaceuticals reported 551,647 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of Vertex Pharmaceuticals includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
In 2024, Vertex Pharmaceuticals reported total Scope 3 emissions of 551,647 metric tons of CO₂ equivalent (tCO₂e). a
Compared to the previous year (2023), Vertex Pharmaceuticals's Scope 3 emissions increased by 16.35%, suggesting that the company faced challenges in reducing emissions across its value chain. a
In 2024, Vertex Pharmaceuticals reported a total carbon footprint of 564,553 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 13.63% increase compared to 2023, suggesting a rise in emissions across its operations or value chain. a b
The largest contributor to Vertex Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 97.71% of the company's total carbon footprint, followed by Scope 1 emissions at 1.59%. a